Identification and functional analysis of a caveolin-3 mutation associated with familial hypertrophic cardiomyopathy
Biochemical and biophysical research communications, 2004•Elsevier
Hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) are caused by
mutations in 14 and 15 different disease genes, respectively, in a part of the patients and the
disease genes for cardiomyopathy overlap in part with that for limb-girdle muscular
dystrophy (LGMD). In this study, we examined an LGMD gene encoding caveolin-3 (CAV3)
for mutation in the patients with HCM or DCM. A Thr63Ser mutation was identified in a
sibling case of HCM. Because the mutation was found at the residue that is involved in the …
mutations in 14 and 15 different disease genes, respectively, in a part of the patients and the
disease genes for cardiomyopathy overlap in part with that for limb-girdle muscular
dystrophy (LGMD). In this study, we examined an LGMD gene encoding caveolin-3 (CAV3)
for mutation in the patients with HCM or DCM. A Thr63Ser mutation was identified in a
sibling case of HCM. Because the mutation was found at the residue that is involved in the …
Hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) are caused by mutations in 14 and 15 different disease genes, respectively, in a part of the patients and the disease genes for cardiomyopathy overlap in part with that for limb-girdle muscular dystrophy (LGMD). In this study, we examined an LGMD gene encoding caveolin-3 (CAV3) for mutation in the patients with HCM or DCM. A Thr63Ser mutation was identified in a sibling case of HCM. Because the mutation was found at the residue that is involved in the LGMD-causing mutations, we investigate the functional change due to the Thr63Ser mutation as compared with the LGMD mutations by examining the distribution of GFP-tagged CAV3 proteins. It was observed that the Thr63Ser mutation reduced the cell surface expression of caveolin-3, albeit the change was mild as compared with the LGMD mutations. These observations suggest that HCM is a clinical spectrum of CAV3 mutations.
Elsevier